Navigation Links
Accelovance Expansion Continues with Acquisition of Radiant Development, the CRO Division of Radiant Research
Date:3/6/2013

ROCKVILLE, Md., March 6, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc. announced today the acquisition of Radiant Development, the CRO division of Radiant Research. This is the latest development in an expansion strategy by the Maryland based CRO that caters to Biotech and small/mid Pharma Sponsors. Terms of the transaction were not disclosed. 

Accelovance is a patient centric CRO offering innovative solutions to meet the needs of its clients. Much of the company's CRO growth has been in the vaccine, infectious disease, and oncology markets. The addition of Radiant Development broadens Accelovance's ability to provide high quality services across a range of therapeutic areas. Radiant Development has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device.  Radiant Development also has specialized expertise in consumer health and nutrition.

"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company.  Core values focused on meeting our client needs, open communication and relationships built on honesty and trust are important similarities between our organizations," remarked Stephen J. Trevisan , Accelovance President and Chief Executive Officer.

Operating out of locations in Stuart, Florida, Chicago, Illinois, and Durham, North Carolina, Radiant Development has managed over 200 research studies since its inception.  Additionally, the company has established strategic partnerships in Europe and Asia to offer clients global study capabilities.  Radiant Development will operate as a division of Accelovance, providing full service clinical capabilities including: project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services.

"With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value to our clients, Radiant Development is delighted to join forces with Accelovance to offer expanded leading edge service solutions to our clients," said Vita Lanoce , Senior Vice President of Development.

Current customers, employees and stake holders of Radiant Development should expect the continued high level of quality, service and performance they are accustomed to receiving.  This includes an ongoing, preferred provider relationship with the Radiant Research and Clinical Research Advantage site network.     

About Accelovance

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies.  The Company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. Accelovance tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs.  Accelovance has a 100% owned subsidiary providing CRO services in China.  These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.  Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to therapeutically aligned studies.

For more information, visit the company's website at http://www.accelovance.com.  

About Radiant Development

Based in Stuart, Florida, Chicago, Illinois and Durham, North Carolina, Radiant Development is a full service CRO offering clinical development services to the biopharmaceutical, biotech, medical device, nutrition and consumer products industries. Our experienced professionals assess and match client's clinical development needs with the services their program requires for success.  

Media Contact:
Garrett D. Smith
Phone: 240.238.4914
gsmith@accelovance.com 


'/>"/>
SOURCE Accelovance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
2. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
3. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
4. HealthEd Taps Kelemen to Lead West Coast Expansion
5. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
6. PolyOne Announces Expansion in Costa Rica with Healthcare-Focused Distribution Services
7. Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and GNC.com
8. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
9. Sentry BioPharma Services Invests in Global Clinical Supply Services with -45C Freezer Expansion
10. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
11. Canada-based Radimetrics Announces Expansion to Scotland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):